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Obtaining sufficient numbers of immunologically matched hematopoietic stem cells (HSCs) poses a major
clinical hurdle in bonemarrow transplantation therapies. In a recent study inCell, Riddell et al. (2014) generate
induced HSCs from differentiated blood cells, which may serve as a potential solution to this clinical
challenge.Bone marrow transplantation (BMT) is
the preferred treatment for a range of dis-
eases where one or more blood cell com-
ponents need to be permanently replaced
or added. Although BMT today is a wide-
spread therapy, several key restrictions
preclude its more extensive use. These
complications include difficulties in
finding immunologically matched donors
and limitations in the numbers of donor
hematopoietic stem cells (HSCs)—the
functional cellular units over time in a
BMT. In a recent issue of Cell, Riddell
et al. (Riddell et al., 2014) demonstrate
the creation of induced HSCs (iHSCs)
from differentiated blood cells. Impor-
tantly, iHSCs exhibit multilineage differ-
entiation potential and extensive self-
renewal in vivo, the hallmark attributes of
normal HSCs following transplantation
(Figure 1).
With the goal of amplifying or gener-
ating transplantable HSCs that can
be used for therapeutic benefit, much
effort has been devoted to achieve
ex vivo expansion of bone-marrow-
derived HSCs (Walasek et al., 2012) or,
alternatively, to generate transplantable
HSCs via differentiation of pluripotent
stem cells (PSCs) (Olsen et al., 2006).
However, the ultimate goal of obtaining
the transplantable properties of HSCs
in vitro with either of these approaches
has so far not been met, which has un-
derscored the need for exploring alterna-
tive strategies. Spurred by the successes
in transcription-factor-mediated reprog-
ramming in recent years (Takahashi and
Yamanaka, 2006), a more novel concept
that has been put forward is to convert
differentiated somatic cells into trans-plantable HSCs through respecification.
Using this experimental paradigm, Szabo
et al. (2010) reported that ectopic expres-
sion of a transcription factor (OCT4)
could induce the generation of multipo-
tent hematopoietic cells from human
fibroblasts. More recently, Pereira et al.
(2013) found that the introduction of
a limited panel of hematopoietic tran-
scription factors (Gata2, Gfi1b, Fos, and
Etv6) into mouse fibroblasts could induce
an embryonic endothelial/hematopoietic
program, from which hematopoietic
cells resembling HSCs with regard to
gene expression and phenotypes could
emerge. Finally, Doulatov et al. (2013)
combined differentiation of PSCs into he-
matopoietic myeloid precursors with sub-
sequent cellular reprogramming, a strat-
egy that broadened the lineage potential
of otherwise committed myeloid cells.
While these studies have all provided
conceptual evidence that multilineage
hematopoietic potential can be instilled
to non-HSCs, the derivation of HSCs
with robust long-term in vivo repopulating
potential has so far been consistently
unsuccessful.
In the recent report in Cell, Riddell et al.
(2014) initially screened a large number of
gene expression data sets for HSC-asso-
ciated transcription factors. Having iden-
tified a set of 36 transcription factors,
they systematically investigated the ability
of these factors to alter the lineage poten-
tial of B cell committed progenitors (pro-B
cells) in vitro. Accordingly, immunoglob-
ulin (Ig) gene rearrangements could be
used as genetic markers to retrospec-
tively track the identity of the original
donor cells. Using this approach, theyCell Stem Cefound that lineage committed B cells
could occasionally produce multilineage
myeloid colonies with rearranged Ig loci,
indicating either that the cocktail of tran-
scription factors transdifferentiated the
pro-B cells to other (myeloid) lineage-
restricted progenitors or, alternatively,
that the cells had become fully multipo-
tent. To address these possibilities, the
authors adopted a highly original induc-
ible in vivo approach in which the 36-fac-
tor cocktail was first transduced into
a pool of pro-B cells. The transduced
cells were next transplanted into irradi-
ated recipient hosts in conjunction with
transient (2 week) transgenic transcription
factor activation. As a consequence,
Riddell et al. could circumvent the need
to maintain candidate HSCs in vitro.
Remarkably, when analyzing long-term
peripheral blood reconstitution following
transplantation, a fraction of the trans-
planted animals exhibited donor pro-B-
cell-derived multilineage reconstitution
along with establishment of the full reper-
toire of hematopoietic progenitor cells,
including serially transplantable HSCs.
The authors could narrow down the 36-
factor cocktail to 6 necessary factors:
Hlf, Lmo2, Pbx1, Prdm5, Runx1t1, and
Zfp37. Moreover, they found that adding
Meis1 and Mycn and delivering the fac-
tors using polycistronic viruses enhanced
the reprogramming efficacy. In addition,
committed myeloid cells, most remark-
ably from the peripheral blood, were also
found to be amenable to iHSC conver-
sion, thereby extending the repertoire
of candidate donor cells and offering a
highly accessible donor cell source for
making iHSCs.ll 14, May 1, 2014 ª2014 Elsevier Inc. 555
Figure 1. Induced Hematopoietic Stem Cells
The development of all blood cells originates frommultipotent and self-renew-
ing HSCs in the bone marrow. Upon differentiation, the developmental
plasticity for all different blood cell lineages is gradually lost and blood cell pre-
cursors become ‘‘locked’’ to individual blood cell lineages. Recently in Cell,
Riddell et al. (2014) find that the introduction of a set of HSC-associated
transcription factors into lineage-committed blood cells can unlock their fate
options and reprogram them into induced HSCs that harbor all properties
of bona fide HSCs, including multilineage differentiation and self-renewal
potential. HSC, hematopoietic stem cell.
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breaking study, several
questions emerge from the
present work. Using sin-
gle-cell gene expression
profiling, the investigators re-
vealed that iHSCs generated
using the optimal eight-fac-
tor polycistronic viral vectors
clustered closely to normal
HSCs. However, candidate
iHSCs generated using sin-
gle-vector delivery of the
eight factors were more het-
erogeneous, with many indi-
vidual cells exhibiting only a
partial reprogramming pro-
file. Although technical con-
straints might underlie these
observations, in that simulta-neous integration of multiple individual
viruses may be difficult to achieve, future
studies should clarify the underlying
mechanisms and steps of the reprog-
ramming process that ultimately lead
to both partially and fully established
iHSCs. Although Riddell et al. reported
no instance of malignancy, it is note-
worthy that several of the reprogram-
ming factors used to derive iHSCs
are well established and highly potent
leukemic oncogenes. While the intro-
duced factors were only transiently
induced, an elegant approach to circum-
vent continuous (and malignant) trans-
gene expression, further investigation
will be required to rule out the possibility
that partially reprogrammed cells might556 Cell Stem Cell 14, May 1, 2014 ª2014 Elbe predisposed for disease development
in the long term and preferably to avoid
the derivation of such cells completely.
Other future challenges include both
solving technical constraints, such as
optimization of transgene delivery and/
or development of alternative noninte-
grating reprogramming strategies, and
approaching more fundamental biolog-
ical questions, such as determining
whether there are any cellular boundaries
to iHSC reprogramming and perhaps,
most importantly, whether and how the
iHSC technology can be translated to
the human system.
Future challenges and considerations
aside, the approaches and findings pio-
neered by Riddell et al. (2014) representsevier Inc.a conceptually astonishing
and significant leap toward
the elusive goal of generating
functional and long-term re-
populating HSCs for clinical
use. Given the many recent
advances and lessons learned
in the era of iPSC technology,
the stage should now be set
for exploring the full potential
of iHSCs in a highly timely
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